You are here

Current therapies of treatment-induced nausea and vomiting: the building blocks of care

Presentation by Dr. Karin Jordan at the MASCC/ISOO Annual Meeting on 26 June 2015

MASCC15 Helsinn Symposium Karin Jordan

Download slides

This symposium was supported by an educational grant from Helsinn Healthcare SA.

Dr. Jordan provides an overview of current therapies of treatment-induced nausea and vomiting, with a focus on the new NK1 receptor antagonists. She presents recent data on the new antiemetic drugs NEPA (netupitant and palonosetron), rolapitant and fosaprepitant.

Dr. Jordan first reviews the classification of chemotherapy agents based on their emetogenic potential and the various modes of action of the current antiemetics, with a focus on NEPA (netupitant and palonosetron) and rolapitant.

The second part of the presentation deals with the prevention of nausea and vomiting in highly and moderately emetogenic chemotherapy, including a review of the recommendations by the MASCC/ESMO, ASCO and NCCN guidelines.

After that, Dr. Jordan reviews new data on NEPA, rolapitant and fosaprepitant, providing the results of recent studies. She also discusses the special setting of patients receiving carboplatin as carboplatin has the highest emetogenic risk among the moderately emetogenic agents.

Dr. Karin Jordan, Martin Luther University of Halle-Wittenberg, Halle, Germany